HeyJaredJuliette Siegfried
- Indexed articles, last 90 days
- 4
- Latest publication
- Aug 25, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 24, 2026
Latest articles
Venetoclax Concentration Tracking Can Improve Post-Transplant AML/MDS - Oncology Nurse Advisor (opens the original)
Read excerpt
Researchers have identified a target venetoclax blood concentration window of 2605 to 4060 ng/mL for post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to findings published in Hematological Oncology, the target offers clinicians a benchmark for dosing venetoclax plus decitabine after allo-HCT. Researchers at Tianjin First Central Hospital analyzed 58 patients treated between April
Fixed-Dose Inotuzumab Plus Vincristine, Prednisone Yields 97% Response in B-ALL - Oncology Nurse Advisor (opens the original)
Read excerpt
A fixed-dose inotuzumab ozogamicin (INO) regimen combined with vincristine and prednisone (VP) produced an overall response rate of 97.44% after a single induction cycle in adults with newly diagnosed B-cell acute lymphocytic leukemia (B-ALL), according to findings published in Blood Cancer Journal. Overall, 38 of 39 patients reached complete remission. Measurable residual disease (MRD) negativity was documented in 89.74% of the full cohort and 92.11% of those in remission. Investigators enrolle
Machine Learning Nomogram Predicts Survival in Low-HALP BCLC Stage 0-B HCC - Oncology Nurse Advisor (opens the original)
Read excerpt
A machine learning-based nomogram stratified 5-year mortality risk among patients with Barcelona Clinic Liver Cancer (BCLC) stage 0-B hepatocellular carcinoma and low hemoglobin, albumin, lymphocyte, and platelet (HALP) scores, according to a study published in the Journal of Inflammation Research. Investigators at a single center in Beijing retrospectively reviewed 1281 patients treated between 2015 and 2021. A HALP cutoff of 47, derived from time-dependent receiver operating characteristic ana
Redesigned Transplant Program Boosts Survival in ALL - Oncology Nurse Advisor (opens the original)
Read excerpt
A comprehensive redesign of an allogeneic hematopoietic cell transplantation (HCT) program for acute lymphoblastic leukemia (ALL) and other indications was associated with significantly better survival, according to findings published in Transplantation and Cellular Therapy. The new program standardizes recipient and donor selection and emphasizes high-reliability operating procedures. One-year overall survival reached 92.6%, and nonrelapse mortality dropped to 1%. Researchers at the Roswell Par
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.